Author:Bio-four Introduction On March 26, 2025, the TROP2 dual payload ADC drug KH815 developed by Kanghong Biotech received clinical trial approval from the Australian HREC and obtained clinical approval in China on April 16, 2025, making it the world’s first dual payload ADC approved for clinical use.During this year’s AACR conference and related patents made … Read more
Hello everyone, this week I am sharing an article published in JACS titled “Identification of a Highly Cooperative PROTAC Degrader Targeting GTP-Loaded KRAS(On) Alleles.” The corresponding authors are Professors Alessio Ciulli and Kirsten McAulay from the University of Dundee, along with Peter Ettmayer from Boehringer Ingelheim. Their research primarily focuses on the mechanism of action … Read more
“Structure similar to a bottlebrush” In recent years, antibody-drug conjugates (ADCs) have emerged as a novel targeted therapy strategy, achieving precise targeting of cancer cells by covalently linking monoclonal antibodies with small molecule drugs. They have demonstrated good efficacy and safety in the treatment of various cancers. However, traditional ADCs still face many limitations in … Read more
Antibody-drug conjugates (ADCs) have emerged as a promising approach for cancer treatment, garnering significant attention. By combining the selective specificity of monoclonal antibodies with the cytotoxicity of drug molecules, they enhance the therapeutic index, selectively targeting cancer cells while minimizing systemic toxicity. However, several challenges remain: including the selection of appropriate target antigens, enhancing antibodies, … Read more
Friends, please click on the above「Medical Intelligence Hardcore Talk」/ Click on the above「 . . .」/ Select「Set as Star」 By 2025, the global ADC (Antibody-Drug Conjugate) market size will exceed $30 billion, yet the confusion among oncologists remains—half of the patients develop resistance during treatment, 15% experience severe side effects due to off-target effects, not … Read more
ADC, or antibody-drug conjugates, is a term that everyone is likely familiar with. The design concept of ADC originated from Paul Ehrlich’s idea of “magic bullets,” aimed at achieving precise targeted therapy while minimizing damage to normal tissues. As of now, there are 15 ADC drugs approved for market worldwide, with over 400 ADC candidates … Read more
Global Analysis of ADC Drugs: Popular, Emerging Targets and Star Drugs The human epidermal growth factor receptor2 (HER2) is one of the most extensively studied and fruitful targets in ADC drugs.HER2 belongs to the ERBB receptor tyrosine kinase family and is overexpressed or amplified in various epithelial-derived tumors, including breast cancer, gastric cancer, and non-small … Read more
Antibody-drug conjugates (ADCs) are a class of biotherapeutic drugs targeting cancer, combining the targeting capability of monoclonal antibodies (mAbs) with the anticancer efficacy of cytotoxic drugs (Payload). The antibody and payload are linked by a linker, allowing specific drugs to be delivered to cancer cells targeted by the antibody. Once inside the cell, the linked … Read more
Accurately delivering therapeutic cells to the desired site in vivo is an emerging and promising cell therapy. However, targeting therapeutic cells to the affected area in the body can be challenging, especially when using a large number of cells, as excessive cytokine production can lead to an overactive immune response. Utilizing microrobots allows for controllable … Read more
Introduction Antibody-drug conjugates (ADC) therapy has rapidly developed over the past few decades, with 14 products approved globally and over 140 ADCs currently in clinical trials. By 2030, the ADC market is expected to exceed $15 billion. The basic principle of ADCs is that by combining the specificity of monoclonal antibodies with the cytotoxicity of … Read more